Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sarepta Therapeutics, Inc.

< Previous 1 2 Next >
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Present at Upcoming Investor Conferences
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS